Search

Your search keyword '"Mikael A, Ritvos"' showing total 2 results
Start Over Author "Mikael A, Ritvos" Topic antibodies, neutralizing
2 results on '"Mikael A, Ritvos"'

1. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics

Author

Anne J. Jääskeläinen, Pinja Jalkanen, Suvi Kuivanen, Ilkka Julkunen, Pekka Kolehmainen, Jukka Hytönen, Mikael A. Ritvos, Moona Huttunen, Maija Lappalainen, Rickard Lundberg, Lav Tripathi, Arja Pasternack, Sisko Tauriainen, Matti Waris, Tytti Vuorinen, Pamela Österlund, Anu Haveri, Laura Kakkola, Olli Ritvos, Satu Kurkela, Hira Khan, Rauno Naves, Krister Melén, Sari Maljanen, Kaisa Rantasarkka, Medicum, Department of Physiology, Faculty of Medicine, Viral Zoonosis Research Unit, Department of Virology, HUSLAB, Staff Services, Olli Pekka Vapalahti / Principal Investigator, Clinicum, and Growth factor physiology

Subjects
Immunoglobulin A, viruses, serology, Antibodies, Viral, medicine.disease_cause, Immunoglobulin G, Immunoenzyme Techniques, respiratory infection, coronavirus proteins, INFECTION, antibodies, Immunology and Allergy, Medicine, skin and connective tissue diseases, Coronavirus, 11832 Microbiology and virology, 0303 health sciences, biology, Respiratory infection, enzyme immunoassay, 3. Good health, AcademicSubjects/MED00290, Infectious Diseases, CROSS-REACTIVITY, Spike Glycoprotein, Coronavirus, Antibody, Sensitivity and Specificity, COVID-19 Serological Testing, 03 medical and health sciences, Antigen, Neutralization Tests, Major Article, Coronavirus Nucleocapsid Proteins, Humans, neutralizing antibodies, HUMAN CORONAVIRUSES 229E, 030304 developmental biology, SARS-CoV-2, 030306 microbiology, business.industry, fungi, COVID-19, biochemical phenomena, metabolism, and nutrition, Phosphoproteins, Antibodies, Neutralizing, Virology, body regions, Immunoglobulin M, 3121 General medicine, internal medicine and other clinical medicine, Humoral immunity, biology.protein, 3111 Biomedicine, business, RESPONSES
Abstract

Background Primary diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is based on detection of virus RNA in nasopharyngeal swab samples. In addition, analysis of humoral immunity against SARS-CoV-2 has an important role in viral diagnostics and seroprevalence estimates. Methods We developed and optimized an enzyme immunoassays (EIA) using SARS-CoV-2 nucleoprotein (N), S1 and receptor binding domain (RBD) of the viral spike protein, and N proteins from SARS, Middle East respiratory syndrome (MERS), and 4 low-pathogenic human CoVs. Neutralizing antibody activity was compared with SARS-CoV-2 IgG, IgA, and IgM EIA results. Results The sensitivity of EIA for detecting immune response in COVID-19 patients (n = 101) was 77% in the acute phase and 100% in the convalescent phase of SARS-CoV-2 infection when N and RBD were used as antigens in IgG and IgA specific EIAs. SARS-CoV-2 infection significantly increased humoral immune responses against the 229E and NL63 N proteins. S1 and RBD-based EIA results had a strong correlation with microneutralization test results. Conclusions The data indicate a combination of SARS-CoV-2 S1 or RBD and N proteins and analysis of IgG and IgA immunoglobulin classes in sera provide an excellent basis for specific and sensitive serological diagnostics of COVID-19.

Published
2021

2. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants

Author

Milja, Belik, Pinja, Jalkanen, Rickard, Lundberg, Arttu, Reinholm, Larissa, Laine, Elina, Väisänen, Marika, Skön, Paula A, Tähtinen, Lauri, Ivaska, Sari H, Pakkanen, Hanni K, Häkkinen, Eeva, Ortamo, Arja, Pasternack, Mikael A, Ritvos, Rauno A, Naves, Simo, Miettinen, Tarja, Sironen, Olli, Vapalahti, Olli, Ritvos, Pamela, Österlund, Anu, Kantele, Johanna, Lempainen, Laura, Kakkola, Pekka, Kolehmainen, Ilkka, Julkunen, University of Helsinki, Infektiosairauksien yksikkö, Helsinki University Hospital Area, Medicum, Department of Physiology, Faculty of Medicine, Department of Virology, HUSLAB, Helsinki One Health (HOH), Viral Zoonosis Research Unit, Emerging Infections Research Group, Veterinary Biosciences, Veterinary Microbiology and Epidemiology, Growth factor physiology, and Department of Medicine

Subjects
Vaccines, Synthetic, COVID-19 Vaccines, SARS-CoV-2, MULTICENTER, COVID-19, Antibodies, Viral, IMMUNOGENICITY, Antibodies, Neutralizing, 3121 General medicine, internal medicine and other clinical medicine, Humans, BNT162B2, mRNA Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273
Abstract

Vaccination shows efficacy in protecting from COVID-19, but regime and dosing optimization is still ongoing. Here the authors show that BNT162b2, mRNA-1273, or their combination with ChAdOx1 induces similar antibody responses, and those receiving three doses of BNT162b2 induce neutralizing antibodies against the Omicron variant. Two COVID-19 mRNA (of BNT162b2, mRNA-1273) and two adenovirus vector vaccines (ChAdOx1 and Janssen) are licensed in Europe, but optimization of regime and dosing is still ongoing. Here we show in health care workers (n = 328) that two doses of BNT162b2, mRNA-1273, or a combination of ChAdOx1 adenovirus vector and mRNA vaccines administrated with a long 12-week dose interval induce equally high levels of anti-SARS-CoV-2 spike antibodies and neutralizing antibodies against D614 and Delta variant. By contrast, two doses of BNT162b2 with a short 3-week interval induce 2-3-fold lower titers of neutralizing antibodies than those from the 12-week interval, yet a third BNT162b2 or mRNA-1273 booster dose increases the antibody levels 4-fold compared to the levels after the second dose, as well as induces neutralizing antibody against Omicron BA.1 variant. Our data thus indicates that a third COVID-19 mRNA vaccine may induce cross-protective neutralizing antibodies against multiple variants.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results